Eiger chalks up one win, one loss between a pair of PhII rare disease drugs, reshuffling priorities
Months after Eiger Biopharmaceuticals conceded ubenimex had no effect in pulmonary arterial hypertension, the drug has proven to be a flop again — this time in lower leg lymphedema.
When compared to placebo in a Phase II study, patients on ubenimex showed no improvement in the swelling on their limbs, whether measured by skin thickness (primary endpoint) nor limb volume and bioimpedance (secondary endpoint).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
